Dr Evie Jackson

Dr Evie Jackson

Postdoctoral Fellow

School of Biomedical Sciences and Pharmacy

Career Summary

Biography

Dr Evangeline Jackson is an Early Career Researcher, awarded her PhD in Medical Biochemistry by publication in December 2023. This work focused on molecular mechanisms underpinning the uniformly fatal paediatric brain cancer, ‘diffuse intrinsic pontine glioma’ or ‘DIPG’.  

Dr Jackson is a specialist in DIPG in vitro modelling and biochemical analysis, working as part of the Cancer Signalling Research Group (CSRG), led by Professor Matthew Dun since 2018, based at the University of Newcastle, Hunter Medical Research Institute. DIPG is a highly aggressive cancer, with palliative radiotherapy the only treatment available which has some survival extension and symptom relief. Dr Jackson’s research focuses on harnessing cellular and molecular biology techniques, coupled with high-resolution quantitative proteomics to find new treatments for DIPG. This research utilises patient-derived cell lines in vitro as well as their establishment in vivo to effectively model patient disease, necessary for translation to the clinical setting.

Dr Jackson has highlighted the utility of systems-wide biology approaches through her recent research investigating a therapy which disrupts the energy metabolism of DIPG cancer cells by disrupting normal mitochondrial dysfunction, known as ONC201. However, DIPG cells are able to evade cell death by upregulating compensatory growth and survival pathways, driven by the kinase ‘PI3K’, revealing a new combination treatment target. Therefore, the combination of ONC201 and the PI3K inhibitor, paxalisib, has shown preclinical promise, assisting in the development of the international clinical trial, PNOC022. Dr Jackson continues to expand this research by applying these analytical techniques to other therapies, in order to find clinically-relevant, novel combinations to be used for the treatment of DIPG.

Qualifications

  • Doctor of Philosophy, University of Newcastle
  • Bachelor of Biomedical Science, University of Newcastle
  • Bachelor of Biomedical Science (Honours), University of Newcastle

Keywords

  • Biochemistry
  • Cell biology
  • Diffuse intrinsic pontine glioma (DIPG)
  • Diffuse midline glioma (DMG)
  • Medical Biochemistry
  • Molecular oncology
  • Proteomics

Languages

  • English (Mother)

Fields of Research

Code Description Percentage
321101 Cancer cell biology 70
320506 Medical biochemistry - proteins and peptides (incl. medical proteomics) 30

Professional Experience

UON Appointment

Title Organisation / Department
Postdoctoral Fellow University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Conference (8 outputs)

Year Citation Altmetrics Link
2024 Jackson ER, Duchatel RJ, Fish CJ, Persson ML, Staudt DE, Findlay IJ, Dun MD, 'TARGETING THE ANTIOXIDANT RESPONSE ELEMENT AXIS SENSITIZES DIFFUSE MIDLINE GLIOMA CELLS TO ONC201', NEURO-ONCOLOGY, 26 (2024)
DOI 10.1093/neuonc/noae064.141
Co-authors Ryan Duchatel, Matt Dun
2024 Findlay IJ, Staudt D, Duchatel RJ, Jackson ER, Kearny P, Persson ML, Mcewen H, Smith ND, Vitanza NA, Cain JE, Waszak SM, Hansen M, Alvaro F, Dun MD, 'FUNCTIONAL MULTI-OMIC PROFILING OF THE LANDSCAPE OF DIFFUSE MIDLINE GLIOMAS TO IDENTIFY THERAPEUTIC VULNERABILITIES', NEURO-ONCOLOGY, 26 (2024)
DOI 10.1093/neuonc/noae064.060
Co-authors Matt Dun, Ryan Duchatel
2024 Persson ML, Jackson ER, Duchatel RJ, de la Nava D, Thomas BC, Savary C, Mcewen HP, Beitaki TS, Kearney PS, Findlay IJ, Douglas AM, Larsen MR, Faridi P, Holst J, Mayall J, Hondermarck H, Horvat J, Nixon B, Cartaxo RT, Nazarian J, Hulleman E, Mueller S, Vitanza NA, Koshmann C, Alonso MM, Carvalheiro T, van der Lugt J, Dun MD, 'DRD2 ANTAGONISM RESCUES IMMUNE-TUMOR SURVEILLANCE, WARMING THE TUMOR IMMUNE MICROENVIRONMENT OF DIFFUSE MIDLINE GLIOMA MODELS', NEURO-ONCOLOGY, 26 (2024)
DOI 10.1093/neuonc/noae064.089
Co-authors Brett Nixon, Matt Dun, Ryan Duchatel, Jemma Mayall, Hubert Hondermarck, Jay Horvat
2024 Dun MD, Jackson E, Vo T, Savary C, Riley M, Douglas A, Findlay I, Germon Z, Mannan A, Thomas B, Duchatel R, Jayaraman R, 'TARGETING GENETIC DEPENDENCIES EXPOSES DIFFUSE MIDLINE GLIOMA CELL OF ORIGIN VULNERABILITIES', NEURO-ONCOLOGY, 26 (2024)
DOI 10.1093/neuonc/noae165.0262
Co-authors Zacary Germon, Ryan Duchatel, Matt Dun, Tuan Vo
2023 Duchatel R, Jackson E, Parackal S, Sun C, Daniel P, Mannan A, Findlay I, Staudt D, Germon Z, Laternser S, Kiltschewskij D, Kearney P, Jamaluddin MFB, Douglas A, Beitaki T, Perrson M, Thomas B, Manning E, Murray H, Verrills N, Vilain R, Skerrett-Byrne D, Nixon B, Hua S, DeBock C, Valdes-Mora F, Tsoli M, Ziegler D, Cairns M, Raabe E, Vitanza N, Phoenix T, Koschmann C, Alvaro F, Dayas C, Tinkle C, Eisenstat D, Firestein R, Mueller S, Nazarian J, Cain J, Dun M, 'EXPLOITING THE GENETIC DEPENDENCY ON PI3K/ MTOR SIGNALING FOR THE TREATMENT OF H3-ALTERED DIFFUSE MIDLINE GLIOMA', NEURO-ONCOLOGY, 25 (2023)
Co-authors Muhammad Jamaluddin, Matt Dun, Susan Hua, David Skerrett-Byrne, Brett Nixon, Zacary Germon, Christopher Dayas, Murray Cairns, Ryan Duchatel
2023 Jackson E, Duchatel R, Staudt D, Persson M, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WS, Le Grand M, Kearney P, Douglas A, Findlay I, Germon Z, McEwen H, Beitaki T, Patabendige A, Skerrett-Byrne D, Nixon B, Smith N, Day B, Manoharan N, Nagabushan S, Hansford J, Govender D, McCowage G, Firestein R, Howlett M, Endersby R, Gottardo N, Alvaro F, Waszak S, Larsen M, Sanguino YC, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, Andre N, Hulleman E, Eisenstat D, Vitanza N, Nazarian J, Koschmann C, Mueller S, Cain J, Dun M, 'COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL (NCT05009992).', NEURO-ONCOLOGY, 25 (2023)
Co-authors Zacary Germon, Ryan Duchatel, Brett Nixon, Matt Dun, David Skerrett-Byrne
2020 Sinclair MR, Jackson ER, Mannan A, Douglas A, Duchatel RJ, Dun MD, 'Preclinical assessment of the safety and efficacy of targeting N-terminal histone tails in combination with emerging therapeutics for the treatment of diffuse midline glioma', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 16, 37-37 (2020)
Co-authors Matt Dun, Ryan Duchatel
2020 Woldu AS, Afrin F, Jackson ER, Duchatel RJ, Mannan A, Staudt D, Smith N, Schneider J, Dun MD, 'Investigation of the in vitro antitumor activity of cannabidiol in diffuse midline gliomas', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 16, 33-33 (2020)
Co-authors Jennifer Schneider, Matt Dun, Ryan Duchatel
Show 5 more conferences

Journal article (27 outputs)

Year Citation Altmetrics Link
2026 Kumari P, Germon ZP, Jackson ER, Vo T, Dun MD, 'The redox paradox in HGGs: ROS as drivers and destroyers', Trends in Cancer (2026) [C1]
DOI 10.1016/j.trecan.2026.01.005
Co-authors Tuan Vo, Matt Dun, Zacary Germon
2025 Duchatel R, Jackson E, Findlay I, Vo T, Savary C, Beitaki T, Douglas A, Dun M, 'DMG-29. Targeting oncogenic plasticity in DIPG: A combined paxalisib and avapritinib approach to enhance survival outcomes', Neuro-Oncology Pediatrics, 1 (2025)
DOI 10.1093/neuped/wuaf001.059
Co-authors Matt Dun, Tuan Vo, Ryan Duchatel
2025 Jackson E, Riley M, Duchatel R, McEwen H, Persson M, Findlay I, Beitaki T, Lally M, Douglas A, Kline C, Nazarian J, Koschmann C, Mueller S, Dun M, 'DMG-09. Targeting the PI3K/AKT/mTOR genetic dependency in combination with ONC201 for the treatment of diffuse midline glioma', Neuro-Oncology Pediatrics, 1 (2025)
DOI 10.1093/neuped/wuaf001.039
Co-authors Matt Dun, Ryan Duchatel
2025 Savary C, Persson ML, Jackson ER, Vo T, Duchatel RJ, Douglas AM, de la Fuente LR, Colino-Sanguino Y, Mora FV, Dun MD, 'DMG-08. Single-Cell Analysis of ONC201 and Paxalisib Resistance Mechanisms in Diffuse Intrinsic Pontine Glioma', Neuro-Oncology Pediatrics, 1 (2025)
DOI 10.1093/neuped/wuaf001.038
Co-authors Ryan Duchatel, Tuan Vo, Matt Dun
2025 Jackson E, Duchatel R, Vo T, Savary C, Germon Z, Riley M, McEwen H, Persson M, Findlay I, Beitaki T, Lally M, Douglas A, Rogers MKN, Fonkem E, Franson A, Kline C, Nazarian J, Koschmann C, Mueller S, Dun M, 'EXTH-89. Precision Targeting of PI3K/mTOR in Diffuse Midline Glioma: GCT007 as a Novel Brain-Penetrant PIK3CA Inhibitor', Neuro-Oncology, 27, v359-v360 (2025)
DOI 10.1093/neuonc/noaf201.1422
Co-authors Matt Dun, Zacary Germon, Ryan Duchatel, Tuan Vo
2025 Dun M, Jackson E, Findlay I, Vo T, Savary C, Douglas A, Germon Z, Mannan A, Persson M, Thomas B, Jayaraman R, Newell-Rogers K, Fonkem E, Wu C-C, Ameratunga M, Duchatel R, 'EXTH-83. Exploiting Cell-of-Origin Vulnerabilities to Guide Multimodal Strategies in Diffuse Midline Glioma', Neuro-Oncology, 27, v358-v358 (2025)
DOI 10.1093/neuonc/noaf201.1416
Co-authors Zacary Germon, Matt Dun, Ryan Duchatel, Tuan Vo
2025 Persson M, Savary C, Jackson E, Duchatel R, Bramberger L, de la Nava D, Thomas B, McEwen H, Beitaki T, Findlay I, Douglas A, Larsen M, Faridi P, Holst J, Mayall J, Hondermarck H, Horvat J, Nixon B, Cartaxo R, Nazarian J, Hulleman E, Mueller S, Vitanza N, Koschmann C, Alonso M, Carvalheiro T, van der Lugt J, Dun M, 'DMG-30. ONC201 induces immune-tumor surveillance and alters the tumor immune microenvironment of diffuse midline glioma models', Neuro-Oncology Pediatrics, 1 (2025)
DOI 10.1093/neuped/wuaf001.060
Co-authors Brett Nixon, Matt Dun, Jemma Mayall, Hubert Hondermarck, Ryan Duchatel, Jay Horvat
2025 Duchatel RJ, Savary C, Germon ZP, Riley M, Ziegler DS, Mueller S, Jackson ER, Dun MD, 'Beyond base camp: PI3K/mTOR inhibition for the treatment of pediatric high-grade gliomas', Neuro Oncology, 27, 2789-2803 (2025) [C1]
DOI 10.1093/neuonc/noaf163
Co-authors Ryan Duchatel, Zacary Germon, Matt Dun
2025 Findlay I, Staudt D, Duchatel R, Jackson E, Kearny P, Persson M, McEwen H, Delevaux K, Smith N, Vitanza N, Cain J, Hansen M, Alvaro F, Waszak S, Dun M, 'DMG-16. Integrative proteogenomic analysis for improved therapeutic decision-making in diffuse midline glioma', Neuro-Oncology Pediatrics, 1 (2025)
DOI 10.1093/neuped/wuaf001.046
Co-authors Ryan Duchatel, Matt Dun
2024 Jackson ER, Persson ML, Fish CJ, Findlay IJ, Mueller S, Nazarian J, Hulleman E, van der Lugt J, Duchatel RJ, Dun MD, 'A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered', NEURO-ONCOLOGY, 26, S136-S154 (2024) [C1]
DOI 10.1093/neuonc/noad144
Citations Scopus - 2Web of Science - 6
Co-authors Izac Findlay Uon, Matt Dun, Ryan Duchatel
2024 Arms LM, Duchatel RJ, Jackson ER, Sobrinho PG, Dun MD, Hua S, 'Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma', JOURNAL OF CONTROLLED RELEASE, 370, 835-865 (2024) [C1]
DOI 10.1016/j.jconrel.2024.05.018
Citations Scopus - 1Web of Science - 1
Co-authors Matt Dun, Susan Hua, Ryan Duchatel
2024 Duchatel RJ, Jackson ER, Parackal SG, Kiltschewskij D, Findlay IJ, Mannan A, Staudt DE, Thomas BC, Germon ZP, Laternser S, Kearney PS, Jamaluddin MFB, Douglas AM, Beitaki T, McEwen HP, Persson ML, Hocke EA, Jain V, Aksu M, Manning EE, Murray HC, Verrills NM, Sun CX, Daniel P, Vilain RE, Skerrett-Byrne DA, Nixon B, Hua S, de Bock CE, Colino-Sanguino Y, Valdes-Mora F, Tsoli M, Ziegler DS, Cairns MJ, Raabe EH, Vitanza NA, Hulleman E, Phoenix TN, Koschmann C, Alvaro F, Dayas C, Tinkle CL, Wheeler H, Whittle JR, Eisenstat DD, Firestein R, Mueller S, Valvi S, Hansford JR, Ashley DM, Gregory SG, Kilburn LB, Nazarian J, Cain JE, Dun MD, 'PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma', JOURNAL OF CLINICAL INVESTIGATION, 134 (2024) [C1]
DOI 10.1172/JCI170329
Citations Scopus - 3Web of Science - 8
Co-authors Dylan Kiltschewskij, Murray Cairns, Christopher Dayas, Nikki Verrills, Izac Findlay Uon, Brett Nixon, Ryan Duchatel, Matt Dun, Lizzie Manning, Heather Murray, Muhammad Jamaluddin, Zacary Germon, David Skerrett-Byrne, Susan Hua
2023 Noll A, Myers C, Biery MC, Meechan M, Tahiri S, Rajendran A, Berens ME, Paine D, Byron S, Zhang J, Winter C, Pakiam F, Leary SES, Cole BL, Jackson ER, Dun MD, Foster JB, Evans MK, Pattwell SS, Olsona JM, Vitanza NA, 'Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma', NEOPLASIA, 43 (2023) [C1]
DOI 10.1016/j.neo.2023.100921
Citations Scopus - 1Web of Science - 2
Co-authors Matt Dun
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, Andre N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma', CANCER RESEARCH, 83, 2421-2437 (2023) [C1]
DOI 10.1158/0008-5472.CAN-23-0186
Citations Scopus - 5Web of Science - 30
Co-authors David Skerrett-Byrne, Izac Findlay Uon, Brett Nixon, Ryan Duchatel, Zacary Germon, Matt Dun
2023 Staudt DE, Murray HC, Skerrett-Byrne DA, Smith ND, Jamaluddin MFB, Kahl RGS, Duchatel RJ, Germon ZP, McLachlan T, Jackson ER, Findlay IJ, Kearney PS, Mannan A, McEwen HP, Douglas AM, Nixon B, Verrills NM, Dun MD, 'Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection (vol 19, 48, 2022)', CLINICAL PROTEOMICS, 20 (2023)
DOI 10.1186/s12014-023-09406-z
Co-authors Ryan Duchatel, Brett Nixon, Muhammad Jamaluddin, Zacary Germon, Heather Murray, Matt Dun, David Skerrett-Byrne, Nikki Verrills
2023 Germon ZP, Sillar JR, Mannan A, Duchatel RJ, Staudt D, Murray HC, Findlay IJ, Jackson ER, McEwen HP, Douglas AM, McLachlan T, Schjenken JE, Skerrett-Byrne DA, Huang H, Melo-Braga MN, Plank MW, Alvaro F, Chamberlain J, De Iuliis G, Aitken RJ, Nixon B, Wei AH, Enjeti AK, Huang Y, Lock RB, Larsen MR, Lee H, Vaghjiani V, Cain JE, de Bock CE, Verrills NM, Dun MD, 'Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies', SCIENCE SIGNALING, 16 (2023) [C1]
DOI 10.1126/scisignal.abp9586
Citations Scopus - 2Web of Science - 11
Co-authors Heather Lee, John Schjenken, Heather Murray, David Skerrett-Byrne, Matt Dun, Anoop Enjeti, John Aitken, Geoffry DeiuliIs, Izac Findlay Uon, Ryan Duchatel, Brett Nixon, Zacary Germon, Nikki Verrills
2022 Findlay IJ, De Iuliis GN, Duchatel RJ, Jackson ER, Vitanza NA, Cain JE, Waszak SM, Dun MD, 'Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies', ONCOGENE, 41, 461-475 (2022) [C1]

Diffuse midline glioma (DMG) is a deadly pediatric and adolescent central nervous system (CNS) tumor localized along the midline structures of the brain atop the spinal... [more]

Diffuse midline glioma (DMG) is a deadly pediatric and adolescent central nervous system (CNS) tumor localized along the midline structures of the brain atop the spinal cord. With a median overall survival (OS) of just 9¿11-months, DMG is characterized by global hypomethylation of histone H3 at lysine 27 (H3K27me3), driven by recurring somatic mutations in H3 genes including, HIST1H3B/C (H3.1K27M) or H3F3A (H3.3K27M), or through overexpression of EZHIP in patients harboring wildtype H3. The recent World Health Organization's 5th Classification of CNS Tumors now designates DMG as, 'H3 K27-altered', suggesting that global H3K27me3 hypomethylation is a ubiquitous feature of DMG and drives devastating transcriptional programs for which there are no treatments. H3-alterations co-segregate with various other somatic driver mutations, highlighting the high-level of intertumoral heterogeneity of DMG. Furthermore, DMG is also characterized by very high-level intratumoral diversity with tumors harboring multiple subclones within each primary tumor. Each subclone contains their own combinations of driver and passenger lesions that continually evolve, making precision-based medicine challenging to successful execute. Whilst the intertumoral heterogeneity of DMG has been extensively investigated, this is yet to translate to an increase in patient survival. Conversely, our understanding of the non-genomic factors that drive the rapid growth and fatal nature of DMG, including endogenous and exogenous microenvironmental influences, neurological cues, and the posttranscriptional and posttranslational architecture of DMG remains enigmatic or at best, immature. However, these factors are likely to play a significant role in the complex biological sequelae that drives the disease. Here we summarize the heterogeneity of DMG and emphasize how analysis of the posttranslational architecture may improve treatment paradigms. We describe factors that contribute to treatment response and disease progression, as well as highlight the potential for pharmaco-proteogenomics (i.e., the integration of genomics, proteomics and pharmacology) in the management of this uniformly fatal cancer.

DOI 10.1038/s41388-021-02102-y
Citations Scopus - 6Web of Science - 49
Co-authors Ryan Duchatel, Matt Dun, Izac Findlay Uon, Geoffry DeiuliIs
2022 Staudt DE, Murray HC, Skerrett-Byrne DA, Smith ND, Jamaluddin MFB, Kahl RGS, Duchatel RJ, Germon ZP, McLachlan T, Jackson ER, Findlay IJ, Kearney PS, Mannan A, McEwen HP, Douglas AM, Nixon B, Verrills NM, Dun MD, 'Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection', CLINICAL PROTEOMICS, 19 (2022) [C1]
DOI 10.1186/s12014-022-09385-7
Citations Scopus - 5Web of Science - 4
Co-authors David Skerrett-Byrne, Zacary Germon, Muhammad Jamaluddin, Ryan Duchatel, Brett Nixon, Izac Findlay Uon, Nikki Verrills, Heather Murray, Matt Dun
2022 McLachlan T, Matthews WC, Jackson ER, Staudt DE, Douglas AM, Findlay IJ, Persson ML, Duchatel RJ, Mannan A, Germon ZP, Dun MD, 'B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers', MOLECULAR CANCER RESEARCH, 20, 1711-1723 (2022) [C1]

B-cell lymphoma 6 (BCL6) is a protooncogene in adult and pediatric cancers, first identified in diffuse large B-cell lymphoma (DLBCL) where it acts as a repressor of th... [more]

B-cell lymphoma 6 (BCL6) is a protooncogene in adult and pediatric cancers, first identified in diffuse large B-cell lymphoma (DLBCL) where it acts as a repressor of the tumor suppressor TP53, conferring survival, protection, and maintenance of lymphoma cells. BCL6 expression in normal B cells is fundamental in the regulation of humoral immunity, via initiation and maintenance of the germinal centers (GC). Its role in B cells during the production of high affinity immunoglobins (that recognize and bind specific antigens) is believed to underpin its function as an oncogene. BCL6 is known to drive the self-renewal capacity of leukemia-initiating cells (LIC), with high BCL6 expression in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and glioblastoma (GBM) associated with disease progression and treatment resistance. The mechanisms underpinning BCL6-driven therapy resistance are yet to be uncovered; however, high activity is considered to confer poor prognosis in the clinical setting. BCL6's key binding partner, BCL6 corepressor (BCOR), is frequently mutated in pediatric cancers and appears to act in concert with BCL6. Using publicly available data, here we show that BCL6 is ubiquitously overexpressed in pediatric brain tumors, inversely to BCOR, highlighting the potential for targeting BCL6 in these often lethal and untreatable cancers. In this review, we summarize what is known of BCL6 (role, effect, mechanisms) in pediatric cancers, highlighting the two sides of BCL6 function, humoral immunity, and tumorigenesis, as well as to review BCL6 inhibitors and highlight areas of opportunity to improve the outcomes of patients with pediatric cancer.

DOI 10.1158/1541-7786.MCR-22-0567
Citations Scopus - 4Web of Science - 18
Co-authors Ryan Duchatel, Izac Findlay Uon, Zacary Germon, Matt Dun
2022 Sanguino YC, de la Fuente LR, Kisswani D, Kearney P, Jackson E, Duchatel R, Holliday H, Jabado N, Tsoli M, Ziegler D, Dun M, Mora FV, 'DIPG-37. Exploring the role of the epigenetic factor H2A.Z acetylation in DIPG', Neuro-Oncology, 24, i26-i27 (2022)
DOI 10.1093/neuonc/noac079.094
Co-authors Matt Dun, Ryan Duchatel
2022 Dun MD, Jackson ER, Duchatel RJ, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara S, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Staudt D, Germon ZP, Skerrett-Byrne DA, Nixon B, Smith ND, Hulleman E, Day B, McCowage GB, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, Vitanza NA, Nazarian J, Koschmann C, Cain J, Mueller S, 'DIPG-07. Preclinical and case study results underpinning the phase II clinical trial testing the combination of ONC201 and paxalisib for the treatment of patients with diffuse midline glioma (NCT05009992)', Neuro-Oncology, 24, i18-i19 (2022)
DOI 10.1093/neuonc/noac079.064
Co-authors Izac Findlay Uon, Ryan Duchatel, Matt Dun, David Skerrett-Byrne, Zacary Germon
2022 Persson M, Jackson E, Duchatel R, Bramberger L, McEwen H, Kearney P, Findlay I, Douglas A, Kobbe B, Wagener R, Larsen M, Faridi P, Holst J, Mayall J, Gedye C, Hondermarck H, Horvat J, Nixon B, Cartaxo R, Koschmann C, Valdes-Mora F, Ortega DG, Nazarian J, Alonso MM, Hulleman E, Van der Lugt J, Vitanza N, Mueller S, Dun M, 'TMIC-06. ANTAGONISM OF DRD2 USING ONC201 INCREASED EXPRESSION OF ANTIGEN PRESENTATION PATHWAY PROTEINS IN DIFFUSE MIDLINE GLIOMA, RECRUITING TUMOR INFILTRATING LYMPHOCYTES IN VIVO', Neuro-Oncology, 24, vii272-vii272 (2022)
DOI 10.1093/neuonc/noac209.1050
Co-authors Jay Horvat, Jemma Mayall, Matt Dun, Hubert Hondermarck, Ryan Duchatel, Brett Nixon, Izac Findlay Uon
2022 Findlay I, Staudt D, Kearney P, McEwen H, Duchatel R, Jackson E, Beitaki T, Smith N, Vitanza N, Firestein R, Cain J, Mueller S, Pasquier E, Koschmann C, Hulleman E, Nazarian J, Hansen M, Alvaro F, Davis M, Waszak S, Dun M, 'CSIG-10. PHARMACO-PHOSPHO-PROTEO-GENOMICS OF PEDIATRIC HIGH-GRADE GLIOMAS – A PILOT STUDY', Neuro-Oncology, 24, vii40-vii41 (2022)
DOI 10.1093/neuonc/noac209.159
Co-authors Ryan Duchatel, Matt Dun, Izac Findlay Uon
2022 Jackson E, Duchatel R, Persson M, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara S, Le Grand M, Kearney P, Douglas A, Findlay I, Staudt D, Germon Z, Skerrett-Byrne D, Nixon B, Smith N, Hulleman E, Day B, McCowage G, Alvaro F, Waszak S, Larsen M, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, Vitanza N, Nazarian J, Koschmann C, Cain J, Mueller S, Dun M, 'EXTH-12. PRECLINICAL AND CASE STUDY EXAMINATION OF THE COMBINATION OF THE CLPP AGONIST ONC201 WITH THE PI3K/AKT INHIBITOR PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA', Neuro-Oncology, 24, vii211-vii211 (2022)
DOI 10.1093/neuonc/noac209.811
Co-authors Zacary Germon, Brett Nixon, David Skerrett-Byrne, Matt Dun, Ryan Duchatel, Izac Findlay Uon
2021 Duchatel RJ, Mannan A, Woldu AS, Hawtrey T, Hindley PA, Douglas AM, Jackson ER, Findlay IJ, Germon ZP, Staudt D, Keamey PS, Smith ND, Hindley KE, Cain JE, Andre N, La Madrid AM, Nixon B, De Luliis GN, Nazarian J, Irish K, Alvaro F, Eisenstat DD, Beck A, Vitanza NA, Mueller S, Morris JC, Dun MD, 'Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma', NEURO-ONCOLOGY ADVANCES, 3 [C1]
DOI 10.1093/noajnl/vdab169
Citations Scopus - 4Web of Science - 28
Co-authors Matt Dun, Brett Nixon, Geoffry DeiuliIs, Zacary Germon, Izac Findlay Uon, Ryan Duchatel
2020 Jackson ER, Duchatel RJ, Mannan A, Hulleman E, Carcaboso AM, Monje M, McCowage GB, Alvaro F, Dun MD, 'AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', NEURO-ONCOLOGY, 22, 293-293 (2020)
Co-authors Ryan Duchatel, Matt Dun
2020 Duchatel RJ, Mannan A, Jackson ER, Staudt D, Skerrett-Byrne DA, Jamaluddin MFB, Woldu AS, Douglas A, Hulleman E, Carcaboso AM, Monje M, Alvaro F, Tsoli M, Ziegler DS, Dun MD, 'DIPG-29. PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE (PI3K) INHIBITION DRIVES PROTEIN KINASE C ACTIVATION (PKC) IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', Neuro-oncology, 22, iii292-iii293 (2020)
Co-authors Muhammad Jamaluddin, Ryan Duchatel, David Skerrett-Byrne, Matt Dun
Show 24 more journal articles

Other (18 outputs)

Year Citation Altmetrics Link
2025 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2025)
DOI 10.1158/0008-5472.c.6651055
Co-authors Zacary Germon, Izac Findlay Uon, David Skerrett-Byrne, Matt Dun, Ryan Duchatel
2025 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2025)
DOI 10.1158/0008-5472.30700396
Co-authors Zacary Germon, Izac Findlay Uon, Ryan Duchatel, David Skerrett-Byrne, Matt Dun, Brett Nixon
2025 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2025)
DOI 10.1158/0008-5472.30700393
Co-authors Izac Findlay Uon, Zacary Germon, David Skerrett-Byrne, Matt Dun, Brett Nixon, Ryan Duchatel
2024 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdés-Mora F, Rakotomalala A, Meignan S, Pasquier E, Andre N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma' (2024)
DOI 10.1158/0008-5472.27027764
Co-authors Ryan Duchatel, Brett Nixon, Izac Findlay Uon, Zacary Germon, David Skerrett-Byrne, Matt Dun
2024 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdés-Mora F, Rakotomalala A, Meignan S, Pasquier E, Andre N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma' (2024)
DOI 10.1158/0008-5472.27027764.v1
Co-authors Zacary Germon, David Skerrett-Byrne, Matt Dun, Izac Findlay Uon, Brett Nixon, Ryan Duchatel
2024 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdés-Mora F, Rakotomalala A, Meignan S, Pasquier E, Andre N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma' (2024)
DOI 10.1158/0008-5472.27027767
Co-authors Zacary Germon, David Skerrett-Byrne, Matt Dun, Ryan Duchatel, Brett Nixon, Izac Findlay Uon
2024 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdés-Mora F, Rakotomalala A, Meignan S, Pasquier E, Andre N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma' (2024)
DOI 10.1158/0008-5472.27027767.v1
Co-authors Izac Findlay Uon, Zacary Germon, David Skerrett-Byrne, Matt Dun, Ryan Duchatel, Brett Nixon
2024 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdés-Mora F, Rakotomalala A, Meignan S, Pasquier E, Andre N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma' (2024)
DOI 10.1158/0008-5472.c.6651055.v3
Co-authors Izac Findlay Uon, Zacary Germon, David Skerrett-Byrne, Matt Dun, Ryan Duchatel, Brett Nixon
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2023)
DOI 10.1158/0008-5472.22892044
Co-authors Matt Dun, David Skerrett-Byrne, Ryan Duchatel, Izac Findlay Uon, Zacary Germon
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2023)
DOI 10.1158/0008-5472.22892044.v1
Co-authors Ryan Duchatel, Izac Findlay Uon, Zacary Germon, Matt Dun, David Skerrett-Byrne
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2023)
DOI 10.1158/0008-5472.22892047
Co-authors Ryan Duchatel, Matt Dun, David Skerrett-Byrne, Zacary Germon, Izac Findlay Uon
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2023)
DOI 10.1158/0008-5472.22892047.v1
Co-authors Matt Dun, David Skerrett-Byrne, Ryan Duchatel, Zacary Germon, Izac Findlay Uon
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2023)
DOI 10.1158/0008-5472.c.6651055.v1
Co-authors Izac Findlay Uon, Ryan Duchatel, Brett Nixon, David Skerrett-Byrne, Matt Dun, Zacary Germon
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2023)
DOI 10.1158/0008-5472.23683824
Co-authors Zacary Germon, Izac Findlay Uon, David Skerrett-Byrne, Matt Dun, Ryan Duchatel
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2023)
DOI 10.1158/0008-5472.23683824.v1
Co-authors David Skerrett-Byrne, Matt Dun, Zacary Germon, Ryan Duchatel, Izac Findlay Uon
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2023)
DOI 10.1158/0008-5472.23683827
Co-authors Matt Dun, David Skerrett-Byrne, Ryan Duchatel, Izac Findlay Uon, Zacary Germon
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2023)
DOI 10.1158/0008-5472.23683827.v1
Co-authors Izac Findlay Uon, Zacary Germon, Matt Dun, David Skerrett-Byrne, Ryan Duchatel
2023 Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (2023)
DOI 10.1158/0008-5472.c.6651055.v2
Co-authors Izac Findlay Uon, Zacary Germon, Matt Dun, David Skerrett-Byrne, Ryan Duchatel
Show 15 more others

Preprint (6 outputs)

Year Citation Altmetrics Link
2025 Duchatel RJ, Savary C, Germon ZP, Riley M, Ziegler DS, Mueller S, Jackson E, Dun MD, 'Beyond Base Camp: Promise and Pitfalls of PI3K/mTOR Inhibition in Pediatric High- Grade Gliomas.' (2025)
DOI 10.21203/rs.3.rs-6508597/v1
Co-authors Zacary Germon, Ryan Duchatel, Matt Dun
2024 Staudt D, Germon Z, Mannan A, McLachlan T, Murray H, Duchatel R, Thomas B, Beitaki T, McEwen H, Persson M, Calvert L, Findlay I, Jackson E, Smith N, Skerrett-Byrne D, Mossman D, Nixon B, De Iullis G, Douglas A, Enjeti A, Sillar J, Chamberlain J, Alvaro F, Wei A, Connerty P, Verrills N, Dun M, 'Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signalling' (2024)
DOI 10.1101/2024.07.26.605229
Co-authors Nikki Verrills, Zacary Germon, David Skerrett-Byrne, Matt Dun, Anoop Enjeti, Brett Nixon, Ryan Duchatel, Heather Murray
2023 Duchatel R, Jackson E, Parackal S, Sun C, Daniel P, Mannan A, Findlay I, Staudt D, Germon Z, Laternser S, Kiltschewskij D, Kearney P, Fairuz M, Jamaluddin B, Douglas A, Beitaki T, Persson M, Manning E, Murray H, Verrills N, Skerrett-Byrne D, Nixon B, Hua S, Fatima V-M, Tsoli M, Ziegler D, Cairns M, Raabe E, Vitanza N, Koschmann C, Alvaro F, Dayas C, Tinkle C, Eisenstat D, Firestein R, Mueller S, Nazarian J, Cain J, Dun M, 'PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma' (2023)
DOI 10.1101/2023.04.17.537256
Co-authors Heather Murray, Lizzie Manning, Murray Cairns, David Skerrett-Byrne, Matt Dun, Muhammad Jamaluddin, Ryan Duchatel, Brett Nixon, Zacary Germon, Christopher Dayas, Nikki Verrills, Susan Hua
2022 Germon Z, Sillar J, Mannan A, Duchatel R, Staudt D, Murray H, Findlay I, Jackson E, McEwen H, Douglas A, McLachlan T, Schjenken J, Skerrett-Bryne D, Huang H, Melo-Braga M, Plank M, Alvaro F, Chamberlain J, Iuliis GD, Aitken J, Nixon B, Wei A, Enjeti A, Lock R, Larsen M, Lee H, de Bock C, Verrills N, Dun M, 'Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies' (2022)
DOI 10.1101/2022.03.09.483687
Co-authors Zacary Germon, Ryan Duchatel, Matt Dun, Izac Findlay Uon, Geoffry DeiuliIs, John Schjenken, Anoop Enjeti, Nikki Verrills, Heather Murray, Heather Lee
2022 Staudt D, Murray H, Skerrett-Byrne D, Smith N, Jamaluddin M, Kahl RGS, Duchatel R, Germon Z, McLachlan T, Jackson E, Findlay I, Kearney P, Mannan A, McEwen H, Douglas A, Nixon B, Verrills N, Dun M, 'High-Throughput Global Phosphoproteomic Profiling Using Phospho Heavy-Labeled-Spiketide FAIMS Stepped-CV DDA (pHASED)' (2022)
DOI 10.1101/2022.04.22.489124
Co-authors Brett Nixon, Zacary Germon, Muhammad Jamaluddin, Matt Dun, David Skerrett-Byrne, Ryan Duchatel, Heather Murray, Nikki Verrills
2022 Staudt D, Murray H, Skerrett-Byrne D, Smith N, Jamaluddin M, Kahl RGS, Duchatel R, Germon Z, McLachlan T, Jackson E, Findlay I, Kearney P, Mannan A, McEwen H, Douglas A, Nixon B, Verrills N, Dun M, 'Phospho heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection' (2022)
DOI 10.21203/rs.3.rs-2152430/v1
Co-authors David Skerrett-Byrne, Heather Murray, Nikki Verrills, Zacary Germon, Brett Nixon, Ryan Duchatel, Matt Dun
Show 3 more preprints
Edit

Grants and Funding

Summary

Number of grants 9
Total funding $24,732,349

Click on a grant title below to expand the full details for that specific grant.

20261 grants / $18,924,091

Advancing Brain-Penetrant PKC Inhibitors to Combat High-Grade Glioma$18,924,091

Funding body: Department of Health, Disability and Ageing

Funding body Department of Health, Disability and Ageing
Project Team Prof Matt Dun, Dr Michelle Monje, Dr Ryan Duchatel, Dr Evie Jackson, Dr Fatima Valdes Mora, Associate Professor Helen Wheeler, Prof Doan Ngo, Assoc Prof Gerard Kaiko, Iliya Dragutinovic, David Eisenstat, Jordan Hansford, Catherine Johnson, Eng-Siew Koh, Associate Professor Jonathan Morris, Un-named student, Un-named student, Ernst Wolvetang
Scheme MRFF - Frontier Health and Medical Research
Role Investigator
Funding Start 2026
Funding Finish 2031
GNo G2301504
Type Of Funding C1300 - Aust Competitive - Medical Research Future Fund
Category 1300
UON Y

20255 grants / $3,985,258

Sequential & Temporal Therapeutic Agility for the Treatment of Diffuse Midline Glioma$2,016,551

Funding body: Department of Health and Aged Care

Funding body Department of Health and Aged Care
Project Team Prof Matt Dun, Dr Ryan Duchatel, Dr Tuan Vo, Dr Evie Jackson, Dr Fatima Valdes Mora, Prof Dieter Heiland, Prof Nada Jabado, Doctor Sebastian Waszak, Dr Sabine Mueller, Associate Professor Mark Cowley, Dr Nicolas Vitanza, Mr Robert Salomon, Dr Laura de la Fuente, Dr Yolanda Sanguino, Miss Olive Loughnan, Santosh Valvi
Scheme MRFF - Paediatric Brain Cancer Research Stream 2
Role Investigator
Funding Start 2025
Funding Finish 2028
GNo G2400646
Type Of Funding C1300 - Aust Competitive - Medical Research Future Fund
Category 1300
UON Y

Sequential & Temporal Therapeutic Agility for the Treatment of Diffuse Midline Glioma$874,879

Funding body: RUN DIPG

Funding body RUN DIPG
Project Team Prof Matt Dun, Associate Professor Mark Cowley, Dr Ryan Duchatel, Professor Henrik Heiland, Professor Nada Jabado, Dr Evie Jackson, Doctor Sabine Mueller, Doctor Laura Rodriguez de la Fuente, Robert Salomon, Yolanda Sanguino, Dr Fatima Valdes Mora, Santosh Valvi, Dr Nicolas Vitanza, Dr Tuan Vo, Doctor Sebastian Waszak
Scheme Research Grant
Role Investigator
Funding Start 2025
Funding Finish 2027
GNo G2500252
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

Sequential & Temporal Therapeutic Agility for the Treatment of Diffuse Midline Glioma$874,879

Funding body: Little Legs Foundation

Funding body Little Legs Foundation
Project Team Prof Matt Dun, Associate Professor Mark Cowley, Dr Ryan Duchatel, Professor Henrik Heiland, Professor Nada Jabado, Dr Evie Jackson, Doctor Sabine Mueller, Doctor Laura Rodriguez de la Fuente, Robert Salomon, Dr Fatima Valdes Mora, Dr Nicolas Vitanza, Dr Tuan Vo, Doctor Sebastian Waszak
Scheme Research Grant
Role Investigator
Funding Start 2025
Funding Finish 2027
GNo G2500253
Type Of Funding C3200 – Aust Not-for Profit
Category 3200
UON Y

Sequential & Temporal Therapeutic Agility for the Treatment of Diffuse Midline Glioma$199,999

Funding body: Mark Hughes Foundation

Funding body Mark Hughes Foundation
Project Team Prof Matt Dun, Associate Professor Mark Cowley, Dr Ryan Duchatel, Professor Henrik Heiland, Professor Nada Jabado, Dr Evie Jackson, Doctor Sabine Mueller, Doctor Laura Rodriguez de la Fuente, Robert Salomon, Yolanda Sanguino, Dr Fatima Valdes Mora, Santosh Valvi, Dr Nicolas Vitanza, Dr Tuan Vo, Doctor Sebastian Waszak
Scheme Research Funding
Role Investigator
Funding Start 2025
Funding Finish 2028
GNo G2500254
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

Advancing Brain-Penetrant PKC Inhibitors to Combat High-Grade Glioma$18,950

Funding body: RUN DIPG

Funding body RUN DIPG
Project Team Prof Matt Dun, Dr Ryan Duchatel, Dr Evie Jackson, Prof Doan Ngo, Assoc Prof Gerard Kaiko, Associate Professor Jonathan Morris, Dr Michelle Monje, Jordan Hansford, Ernst Wolvetang, David Eisenstat, Eng-Siew Koh, Iliya Dragutinovic, Dr Fatima Valdes Mora, Associate Professor Helen Wheeler, Catherine Johnson
Scheme Research Grant
Role Investigator
Funding Start 2025
Funding Finish 2026
GNo G2501175
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

20242 grants / $623,000

Targeting the metabolic dependencies of diffuse midline glioma$510,000

Funding body: The Kids' Cancer Project (TKCP)

Funding body The Kids' Cancer Project (TKCP)
Project Team Dr Evie Jackson, Prof Matt Dun, Dr Evie Jackson, Dr Evie Jackson
Scheme Col Reynolds Fellowship - Early Career
Role Lead
Funding Start 2024
Funding Finish 2026
GNo G2301313
Type Of Funding C1700 - Aust Competitive - Other
Category 1700
UON Y

Utilising a translational nanopharmaceutics approach to improving drug delivery in diffuse intrinsic pontine glioma$113,000

Funding body: Mark Hughes Foundation

Funding body Mark Hughes Foundation
Project Team Prof Susan Hua, Miss Lauren Arms, Dr Ryan Duchatel, Prof Matt Dun, Dr Evie Jackson
Scheme Innovation Grant
Role Investigator
Funding Start 2024
Funding Finish 2025
GNo G2301481
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

20231 grants / $1,200,000

A chink in the armour of DMG tumours: Exploiting DMG-specific defence systems to improve response to treatment$1,200,000

Funding body: RUN DIPG

Funding body RUN DIPG
Project Team Prof Matt Dun, Dr Evie Jackson, Dr Ryan Duchatel, Miss Evangeline Jackson
Scheme Research Grant
Role Investigator
Funding Start 2023
Funding Finish 2026
GNo G2300913
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y
Edit

Research Supervision

Number of supervisions

Completed0
Current6

Current Supervision

Level of Study Research Title Program Supervisor Type
PhD Improving Drug Delivery Into The Brain Doctor of Philosophy, Graduate Research, The University of Newcastle Co-Supervisor
PhD Targeting the extracellular matrix of paediatric brain tumours to promote response to systemic and immune-based therapies. Doctor of Philosophy, Graduate Research, The University of Newcastle Co-Supervisor
PhD Integrated DMG Multi-omics Subtyping System Doctor of Philosophy, Graduate Research, The University of Newcastle Co-Supervisor
PhD Targeting ROS to Modulate the Epigenome and Improve the Treatment of Diffuse Midline Glioma Doctor of Philosophy, Graduate Research, The University of Newcastle Co-Supervisor
PhD Understanding Therapeutic Adaptability in Difuse Midline Glioma (DMG) Doctor of Philosophy, Graduate Research, The University of Newcastle Co-Supervisor
PhD Optimising Treatment Strategies for Diffuse Midline Glioma utilising Multi-omic Characterisation of DMG Models Doctor of Philosophy, Graduate Research, The University of Newcastle Co-Supervisor
Edit

Dr Evie Jackson

Position

Postdoctoral Fellow
Cancer Signalling Research Group
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing

Contact Details

Email evie.jackson@newcastle.edu.au
Phone 61240550273
Edit